NASDAQ · KNSA
Healthcare · Biotechnology
$79.80
Up+$1.12 (+1.42%)
Updated Aug 28, 2026, 9:00 AM
SID Score
5.5/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
KNSA closed at $79.80 after 21 trading sessions, up 2.05% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $78.20 | $80.79 | $77.80 | $79.80 | 413.27K |
| Aug 26, 2026 | $79.65 | $80.26 | $78.35 | $78.68 | 383.82K |
| Aug 25, 2026 | $79.36 | $80.86 | $79.13 | $80.20 | 402.06K |
| Aug 24, 2026 | $79.50 | $79.98 | $77.71 | $79.38 | 419.05K |
| Aug 21, 2026 | $78.28 | $79.93 | $78.01 | $79.03 | 270.12K |
| Aug 20, 2026 | $79.43 | $80.12 | $77.6388 | $78.47 | 546.88K |
| Aug 19, 2026 | $80.50 | $81.5662 | $79.27 | $80.80 | 872.29K |
| Aug 18, 2026 | $78.85 | $79.86 | $78.77 | $79.49 | 367.33K |
| Aug 17, 2026 | $76.89 | $79.215 | $76.75 | $79.18 | 328.95K |
| Aug 14, 2026 | $77.32 | $77.51 | $75.30 | $76.75 | 403.53K |
| Aug 13, 2026 | $78.65 | $79.69 | $77.195 | $77.83 | 451.33K |
| Aug 12, 2026 | $77.37 | $79.789 | $76.92 | $78.15 | 527.83K |
| Aug 11, 2026 | $76.67 | $78.25 | $75.725 | $77.80 | 350.87K |
| Aug 10, 2026 | $76.05 | $77.78 | $75.00 | $76.53 | 264.63K |
| Aug 7, 2026 | $77.66 | $77.82 | $75.52 | $76.06 | 219.85K |
| Aug 6, 2026 | $77.88 | $78.7999 | $75.74 | $76.51 | 353.32K |
| Aug 5, 2026 | $76.91 | $78.24 | $76.12 | $78.08 | 531.39K |
| Aug 4, 2026 | $75.14 | $76.91 | $73.04 | $75.99 | 661.83K |
| Aug 3, 2026 | $73.89 | $75.4418 | $71.415 | $73.41 | 785.35K |
| Jul 31, 2026 | $77.66 | $78.0365 | $73.65 | $74.34 | 1.03M |
| Jul 30, 2026 | $79.40 | $80.51 | $77.74 | $78.20 | 947.59K |
The latest Smart Investors Daily articles mentioning KNSA.
KNSA research
Company profile and research snapshot.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Goldman Sachs | Buy | — |
| Jul 29, 2026 | Citigroup | Buy | — |
| Jul 29, 2026 | Wedbush | Outperform | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
ChartMill · Aug 18, 2026
Kiniksa Pharma (KNSA) offers strong growth with reasonable valuation, solid profitability, and a clean balance sheet—an affordable growth pick in biotech.
Yahoo · Aug 7, 2026
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximatel
Yahoo · Aug 3, 2026
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
SeekingAlpha · Jul 31, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KNSA.
